168. エーラス・ダンロス症候群 Ehlers-Danlos syndrome Clinical trials / Disease details


臨床試験数 : 8 薬物数 : 17 - (DrugBank : 9) / 標的遺伝子数 : 9 - 標的パスウェイ数 : 55

  
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04890431
(ClinicalTrials.gov)
June 20216/5/2021Impact of Oxygen Therapy on Fatigue in Patients With Hypermobile-type Ehlers-Danlos SyndromeImpact of Oxygen Therapy on Fatigue in Patients With Hypermobile-type Ehlers-Danlos Syndrome: a Randomised Double-blind Placebo-controlled StudyEhlers-Danlos SyndromeDrug: Oxygen;Drug: PlaceboHospital St. Joseph, Marseille, FranceNULLNot yet recruiting18 YearsN/AAll82Phase 4NULL
2NCT04036305
(ClinicalTrials.gov)
July 26, 201925/7/2019Local Anesthetic Response in Ehlers-Danlos Syndrome (EDS) and Healthy VolunteersLocal Anesthetic Response in Ehlers-Danlos Syndrome (EDS) and Healthy VolunteersEhlers-Danlos Syndrome;Anesthesia, LocalDrug: 0.9% Sodium Chloride Injection;Drug: Lidocaine Injection 2%;Drug: Bupivacaine Injection 0.5%Vanderbilt University Medical CenterUniversity of CalgaryEnrolling by invitation18 YearsN/AAll230United States
3NCT02597361
(ClinicalTrials.gov)
January 201623/10/2015Angiotensin II Receptor Blockade in Vascular Ehlers Danlos Syndrome (ARCADE)Angiotensin II Receptor Blockade in Vascular Ehlers Danlos Syndrome: a Double Blind, Randomized, Placebo Controlled, Multicenter Trial.Ehlers-Danlos Syndrome, Vascular TypeDrug: Irbesartan;Drug: PlaceboAssistance Publique - Hôpitaux de ParisMinistry of Health, FranceCompleted18 Years70 YearsAll61Phase 3France
4EUCTR2015-001065-76-FR
(EUCTR)
28/09/201508/09/2015N/AN/A - ARCADE
MedDRA version: 18.0;Level: PT;Classification code 10014316;Term: Ehlers-Danlos syndrome;System Organ Class: 10010331 - Congenital, familial and genetic disorders
Trade Name: IRBESARTAN
Product Name: IRBESARTAN
INN or Proposed INN: irbesartan
ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)NULLNot RecruitingFemale: yes
Male: yes
169Phase 3France
5NCT01446783
(ClinicalTrials.gov)
September 201127/9/2011IGF-I Stimulation of Collagen Synthesis in Ehlers-Danlos PatientsIGF-I Stimulation of Collagen Synthesis in Ehlers-Danlos PatientsEhlers-Danlos Syndrome, ClassicDrug: mecasermin;Drug: SalineBispebjerg HospitalNULLCompleted18 YearsN/ABoth15N/ADenmark
6NCT01307527
(ClinicalTrials.gov)
November 20081/3/2011Riboflavin Corneal Crosslinking for Brittle Cornea Syndrome and Ehlers-Danlos Syndrome Type VIBrittle Cornea Syndrome;Ehlers-Danlos Syndrome Type 6Drug: Riboflavin;Device: Kera-XHadassah Medical OrganizationNULLEnrolling by invitation18 YearsN/ABoth1N/AIsrael
7NCT00190411
(ClinicalTrials.gov)
October 200313/9/2005Celiprolol in Patients With Ehlers-Danlos Syndrome, Vascular TypePrevention of Vascular Complications by BetaBlocker Treatment in Vascular Ehlers-Danlos SyndromeEHLERS-DANLOS SYNDROME, TYPE IV, AUTOSOMAL DOMINANT;CHROMOSOME 2q31.2 DELETION SYNDROMEDrug: celiprolol;Drug: ControlAssistance Publique - Hôpitaux de ParisAventis PharmaceuticalsCompleted15 Years65 YearsBoth54Phase 4France
8NCT00001966
(ClinicalTrials.gov)
January 200018/1/2000Mind-Body Therapy for Pain in Ehlers-Danlos SyndromeA Pilot Study of Mind-Body Therapy for Chronic Pain in Ehlers-Danlos SyndromeEhlers-Danlos Syndrome;PainDrug: Mind-body therapyNational Human Genome Research Institute (NHGRI)NULLCompletedN/AN/ABoth40Phase 2United States